GW Henssler & Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $274K | Sell |
7,450
-509
| -6% | -$24.1K | 0.01% | 179 |
|
|
2025
Q4 | $405K | Hold |
7,959
| – | – | 0.02% | 147 |
|
|
2025
Q3 | $442K | Hold |
7,959
| – | – | 0.02% | 139 |
|
|
2025
Q2 | $549K | Hold |
7,959
| – | – | 0.03% | 123 |
|
|
2025
Q1 | $553K | Sell |
7,959
-500
| -6% | -$41.3K | 0.03% | 116 |
|
|
2024
Q4 | $1.01M | Hold |
8,459
| – | – | 0.06% | 92 |
|
|
2024
Q3 | $1.01M | Hold |
8,459
| – | – | 0.06% | 93 |
|
|
2024
Q2 | $1.21M | Hold |
8,459
| – | – | 0.07% | 87 |
|
|
2024
Q1 | $1.09M | Hold |
8,459
| – | – | 0.06% | 85 |
|
|
2023
Q4 | $875K | Sell |
8,459
-655
| -7% | -$64.8K | 0.06% | 90 |
|
|
2023
Q3 | $829K | Hold |
9,114
| – | – | 0.06% | 89 |
|
|
2023
Q2 | $737K | Hold |
9,114
| – | – | 0.05% | 92 |
|
|
2023
Q1 | $725K | Hold |
9,114
| – | – | 0.05% | 93 |
|
|
2022
Q4 | $617K | Sell |
9,114
-506
| -5% | -$29.7K | 0.04% | 96 |
|
|
2022
Q3 | $479K | Sell |
9,620
-550
| -5% | -$29.5K | 0.04% | 100 |
|
|
2022
Q2 | $567K | Sell |
10,170
-132
| -1% | -$7.33K | 0.04% | 97 |
|
|
2022
Q1 | $572K | Sell |
10,302
-3,272
| -24% | -$168K | 0.03% | 107 |
|
|
2021
Q4 | $760K | Buy |
+13,574
| New | +$735K | 0.05% | 102 |
|
|
2021
Q3 | – | Sell |
-15,606
| Closed | -$654K | – | 186 |
|
|
2021
Q2 | $654K | Sell |
15,606
-2,808
| -15% | -$109K | 0.04% | 105 |
|
|
2021
Q1 | $621K | Sell |
18,414
-385,168
| -95% | -$13.7M | 0.04% | 107 |
|
|
2020
Q4 | $14.1M | Buy |
403,582
+1,830
| +0.5% | +$63.3K | 1.08% | 39 |
|
|
2020
Q3 | $13.9M | Sell |
401,752
-386,188
| -49% | -$12.9M | 1.18% | 40 |
|
|
2020
Q2 | $25.8M | Buy |
787,940
+40,570
| +5% | +$1.29M | 2.27% | 5 |
|
|
2020
Q1 | $22.5M | Buy |
747,370
+149,000
| +25% | +$4.44M | 2.28% | 3 |
|
|
2019
Q4 | $17.3M | Buy |
598,370
+33,800
| +6% | +$936K | 1.43% | 26 |
|
|
2019
Q3 | $14.6M | Buy |
564,570
+33,296
| +6% | +$842K | 1.3% | 29 |
|
|
2019
Q2 | $13.6M | Buy |
531,274
+20,168
| +4% | +$498K | 1.23% | 35 |
|
|
2019
Q1 | $13.4M | Buy |
511,106
+23,272
| +5% | +$572K | 1.23% | 33 |
|
|
2018
Q4 | $11.2M | Buy |
487,834
+44,432
| +10% | +$987K | 1.2% | 34 |
|
|
2018
Q3 | $10.5M | Buy |
443,402
+28,440
| +7% | +$694K | 0.95% | 48 |
|
|
2018
Q2 | $9.57M | Buy |
414,962
+33,696
| +9% | +$801K | 0.94% | 47 |
|
|
2018
Q1 | $9.39M | Buy |
381,266
+39,978
| +12% | +$1.05M | 0.94% | 50 |
|
|
2017
Q4 | $9.16M | Buy |
341,288
+81,336
| +31% | +$2.07M | 0.86% | 52 |
|
|
2017
Q3 | $6.26M | Buy |
259,952
+15,518
| +6% | +$351K | 0.63% | 64 |
|
|
2017
Q2 | $5.24M | Buy |
244,434
+10,338
| +4% | +$209K | 0.55% | 65 |
|
|
2017
Q1 | $4.01M | Buy |
234,096
+25,190
| +12% | +$439K | 0.43% | 69 |
|
|
2016
Q4 | $3.75M | Buy |
+208,906
| New | +$3.79M | 0.41% | 70 |
|
Other funds holding NVO
DAM
F
GW Henssler & Associates's NVO Position: Q1 2026 in Review
GW Henssler & Associates reduced its Novo Nordisk (NVO) stake by 6.4% in Q1 2026, selling an estimated $24.1K and leaving 7,450 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #179.
GW Henssler & Associates first reported a position in NVO in Q4 2016 and has held it in 37 quarters since. The position peaked at $25.8M in Q2 2020. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- GW Henssler & Associates held 7,450 shares of Novo Nordisk worth $274K as of Q1 2026.
- GW Henssler & Associates sold 509 Novo Nordisk shares in Q1 2026, an estimated $24.1K.
- Novo Nordisk made up 0.01% of GW Henssler & Associates's portfolio in Q1 2026, its #179 holding.
- GW Henssler & Associates first reported a position in Novo Nordisk in Q4 2016 and has held it in 37 quarters since.
- GW Henssler & Associates's Novo Nordisk position peaked at $25.8M in Q2 2020.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on GW Henssler & Associates's 13F filing for Q1 2026, filed 15 May 2026.